
Alcon (ALC) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
2.5B
Gross Profit
1.4B
55.92%
Operating Income
468.0M
18.92%
Net Income
350.0M
14.15%
EPS (Diluted)
$0.70
Balance Sheet Metrics
Total Assets
31.0B
Total Liabilities
9.0B
Shareholders Equity
22.0B
Debt to Equity
0.41
Cash Flow Metrics
Free Cash Flow
384.0M
Revenue & Profitability Trend
Alcon Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 9.9B | 9.5B | 8.7B | 8.3B | 6.8B |
Cost of Goods Sold | 4.4B | 4.2B | 4.0B | 3.6B | 3.9B |
Gross Profit | 5.5B | 5.2B | 4.7B | 4.7B | 2.9B |
Gross Margin % | 55.6% | 55.5% | 54.5% | 56.1% | 43.0% |
Operating Expenses | |||||
Research & Development | 876.0M | 828.0M | 702.0M | 842.0M | 673.0M |
Selling, General & Administrative | 3.2B | 3.2B | 3.1B | 3.1B | 2.7B |
Other Operating Expenses | -27.0M | 171.0M | 306.0M | 154.0M | 55.0M |
Total Operating Expenses | 4.1B | 4.2B | 4.1B | 4.1B | 3.4B |
Operating Income | 1.4B | 1.0B | 672.0M | 580.0M | -482.0M |
Operating Margin % | 14.3% | 11.0% | 7.7% | 7.0% | -7.1% |
Non-Operating Items | |||||
Interest Income | 84.0M | 45.0M | 16.0M | 3.0M | 6.0M |
Interest Expense | 192.0M | 189.0M | 134.0M | 120.0M | 124.0M |
Other Non-Operating Income | -37.0M | -52.0M | -79.0M | -35.0M | -26.0M |
Pre-tax Income | 1.3B | 832.0M | 463.0M | 418.0M | -635.0M |
Income Tax | 238.0M | -142.0M | 128.0M | 42.0M | -104.0M |
Effective Tax Rate % | 18.9% | -17.1% | 27.6% | 10.0% | 0.0% |
Net Income | 1.0B | 974.0M | 335.0M | 376.0M | -531.0M |
Net Margin % | 10.3% | 10.3% | 3.8% | 4.5% | -7.8% |
Key Metrics | |||||
EBITDA | 2.7B | 2.3B | 1.8B | 1.8B | 1.1B |
EPS (Basic) | $2.06 | $1.98 | $0.68 | $0.77 | $-1.09 |
EPS (Diluted) | $2.05 | $1.96 | $0.68 | $0.76 | $-1.09 |
Basic Shares Outstanding | 494400000 | 493000000 | 491400000 | 490000000 | 489000000 |
Diluted Shares Outstanding | 494400000 | 493000000 | 491400000 | 490000000 | 489000000 |
Income Statement Trend
Alcon Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.7B | 1.1B | 980.0M | 1.6B | 1.6B |
Short-term Investments | 154.0M | 7.0M | 0 | 3.0M | 12.0M |
Accounts Receivable | 1.9B | 1.9B | 1.8B | 1.6B | 1.5B |
Inventory | 2.3B | 2.3B | 2.1B | 1.9B | 1.6B |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 6.3B | 5.6B | 5.2B | 5.4B | 5.0B |
Non-Current Assets | |||||
Property, Plant & Equipment | 36.0M | 31.0M | 29.0M | 29.0M | 28.0M |
Goodwill | 26.5B | 26.9B | 27.5B | 26.6B | 26.9B |
Intangible Assets | 8.6B | 9.1B | 9.7B | 8.8B | 9.1B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 865.0M | 889.0M | 803.0M | 763.0M | 742.0M |
Total Non-Current Assets | 24.0B | 24.0B | 24.0B | 22.6B | 22.6B |
Total Assets | 30.3B | 29.6B | 29.2B | 28.0B | 27.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 773.0M | 811.0M | 861.0M | 903.0M | 876.0M |
Short-term Debt | 161.0M | 206.0M | 168.0M | 174.0M | 232.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 12.0M | 10.0M | 10.0M | 7.0M | 22.0M |
Total Current Liabilities | 2.3B | 2.5B | 2.7B | 2.5B | 2.3B |
Non-Current Liabilities | |||||
Long-term Debt | 5.0B | 4.9B | 4.9B | 4.3B | 4.3B |
Deferred Tax Liabilities | 724.0M | 797.0M | 1.1B | 1.0B | 1.2B |
Other Non-Current Liabilities | 128.0M | 166.0M | 230.0M | 168.0M | 237.0M |
Total Non-Current Liabilities | 6.5B | 6.5B | 6.8B | 6.3B | 6.5B |
Total Liabilities | 8.8B | 9.0B | 9.5B | 8.7B | 8.8B |
Equity | |||||
Common Stock | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M |
Retained Earnings | - | - | - | - | - |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 21.6B | 20.6B | 19.7B | 19.3B | 18.8B |
Key Metrics | |||||
Total Debt | 5.1B | 5.1B | 5.1B | 4.5B | 4.5B |
Working Capital | 4.0B | 3.2B | 2.5B | 2.9B | 2.7B |
Balance Sheet Composition
Alcon Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.0B | 974.0M | 335.0M | 376.0M | -531.0M |
Depreciation & Amortization | 1.2B | 1.2B | 1.1B | 1.2B | 1.6B |
Stock-Based Compensation | 150.0M | 144.0M | 140.0M | 138.0M | 105.0M |
Working Capital Changes | -189.0M | -404.0M | -522.0M | -314.0M | -45.0M |
Operating Cash Flow | 2.5B | 1.7B | 1.3B | 1.6B | 1.1B |
Investing Activities | |||||
Capital Expenditures | -473.0M | -658.0M | -636.0M | -700.0M | -473.0M |
Acquisitions | -220.0M | -10.0M | -666.0M | 0 | 0 |
Investment Purchases | -278.0M | -233.0M | -50.0M | -19.0M | -11.0M |
Investment Sales | 9.0M | 2.0M | 81.0M | 1.0M | 0 |
Investing Cash Flow | -970.0M | -901.0M | -1.8B | -718.0M | -484.0M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -130.0M | -116.0M | -100.0M | -54.0M | 0 |
Debt Issuance | 59.0M | 29.0M | 2.6B | 52.0M | 744.0M |
Debt Repayment | -196.0M | -113.0M | -2.4B | -115.0M | -69.0M |
Financing Cash Flow | -322.0M | -245.0M | -50.0M | -166.0M | 466.0M |
Free Cash Flow | 1.4B | 537.0M | 472.0M | 165.0M | 256.0M |
Net Change in Cash | 1.2B | 585.0M | -497.0M | 668.0M | 1.1B |
Cash Flow Trend
Alcon Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
40.84
Forward P/E
26.11
Price to Book
2.07
Price to Sales
4.62
PEG Ratio
26.11
Profitability Ratios
Profit Margin
11.28%
Operating Margin
13.30%
Return on Equity
5.23%
Return on Assets
2.74%
Financial Health
Current Ratio
2.70
Debt to Equity
23.63
Beta
0.70
Per Share Data
EPS (TTM)
$2.25
Book Value per Share
$44.39
Revenue per Share
$20.06
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
alc | 45.8B | 40.84 | 2.07 | 5.23% | 11.28% | 23.63 |
Intuitive Surgical | 172.2B | 67.08 | 9.65 | 16.04% | 28.51% | 0.00 |
Becton, Dickinson | 56.3B | 35.89 | 2.21 | 6.18% | 7.41% | 75.93 |
ResMed | 41.7B | 29.93 | 6.99 | 25.86% | 27.22% | 14.27 |
West Pharmaceutical | 17.7B | 36.91 | 6.04 | 17.72% | 16.48% | 10.52 |
Hologic | 15.1B | 28.14 | 3.11 | 11.38% | 13.79% | 52.09 |
Financial data is updated regularly. All figures are in the company's reporting currency.